CorMedix focuses on developing and commercializing therapeutic products to prevent and treat infectious and inflammatory diseases, with a particular emphasis on addressing complications associated with cardiac, renal, metabolic, and infectious conditions. Their range of therapeutic candidates includes small molecules, biologics, chemical entities, devices, and diagnostics. One of their notable achievements is receiving CE Mark approval for Neutrolin®, a catheter lock solution that prevents catheter-related bloodstream infections and maintains catheter patency in hemodialysis patients. CorMedix aims to provide risk mitigation solutions for central venous catheters in various important indications, targeting unmet medical needs in clinical settings such as hemodialysis, total parenteral nutrition, and oncology.